Suppliers and packagers for generic pharmaceutical drug: TELAVANCIN HYDROCHLORIDE

TELAVANCIN HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110	NDA	Cumberland Pharmaceuticals Inc.	66220-315-11	1 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-11) / 50 mL in 1 VIAL, SINGLE-DOSE	2021-01-01
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110	NDA	Cumberland Pharmaceuticals Inc.	66220-315-22	12 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-22) / 50 mL in 1 VIAL, SINGLE-DOSE	2021-01-01
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110	NDA	Cumberland Pharmaceuticals Inc.	66220-315-44	4 VIAL, SINGLE-DOSE in 1 CARTON (66220-315-44) / 50 mL in 1 VIAL, SINGLE-DOSE	2021-01-01

Telavancin Hydrochloride API Suppliers Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and potential supply chain for telavancin hydrochloride, a lipoglycopeptide antibiotic. The analysis identifies key patent holders, manufacturing capabilities, and regulatory considerations relevant to the production of telavancin hydrochloride active pharmaceutical ingredient (API).

What is Telavancin Hydrochloride?

Telavancin hydrochloride is a synthetic lipoglycopeptide antibiotic developed for the treatment of serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action involves disrupting bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, inhibiting transglycosylation and transpeptidation. Additionally, telavancin exhibits membrane-disrupting activity, further contributing to its bactericidal effects [1].

Patent Landscape for Telavancin Hydrochloride

The patent protection surrounding telavancin hydrochloride is a critical factor influencing its market entry and generic competition. Primary patent protection was held by Theravance Inc., with subsequent licensing and commercialization rights held by Ajinomoto Althea and later Pacira BioSciences, Inc. (through its acquisition of Depomed, which had acquired rights from Theravance) [2, 3].

Key patents related to telavancin include those covering its chemical synthesis, crystalline forms, and specific therapeutic uses. For instance, patents such as US 7,879,800 B2 detail processes for synthesizing telavancin. The expiry of these foundational patents opens avenues for generic manufacturers.

Patent Number	Title	Assignee (Original)	Status	Expiry (Approximate)
US 7,879,800	Process for the preparation of lipoglycopeptide compounds	Theravance Inc.	Expired	2025
US 8,138,148	Lipoglycopeptide compounds and their use in treating bacterial infections	Theravance Inc.	Expired	2026
US 8,765,701	Pharmaceutical compositions comprising lipoglycopeptide compounds	Theravance Inc.	Expired	2026

Source: USPTO Patent Database, Commercial Patent Search Engines.

The expiration dates indicate the gradual erosion of exclusivity, allowing for potential market entry by generic API manufacturers. However, ongoing patent filings related to novel formulations, manufacturing improvements, or specific polymorphs may extend effective market control for certain aspects of the drug.

API Manufacturing Considerations

The synthesis of telavancin hydrochloride is a complex, multi-step process. It involves the modification of a natural glycopeptide precursor, typically vancomycin, through semi-synthetic routes. This complexity necessitates specialized manufacturing capabilities, including:

• Fermentation Expertise: For the production of the glycopeptide backbone.
• Chemical Synthesis: For modification steps, including the addition of lipid moieties and other functional groups.
• Purification Technologies: Advanced chromatography and crystallization techniques are required to achieve the high purity standards mandated for pharmaceutical APIs.
• Analytical Characterization: Rigorous analytical methods, including HPLC, NMR, and mass spectrometry, are essential for quality control.

The manufacturing process is described in several patents, providing insights into potential synthesis pathways and challenges. For example, patents often detail specific reagents, reaction conditions, and purification strategies.

Key API Suppliers and Manufacturers

Identifying direct API suppliers for telavancin hydrochloride requires navigating a landscape that includes both original drug innovators and potential generic manufacturers. As of current market analysis, the primary commercial supplier of the finished drug product, VIBATIV®, has been associated with Ajinomoto Althea and subsequently Pacira BioSciences.

However, for generic API production, a different set of manufacturers will emerge. These are typically Contract Development and Manufacturing Organizations (CDMOs) with demonstrated expertise in complex peptide and antibiotic synthesis. While specific public lists of telavancin hydrochloride API manufacturers are not readily available due to competitive proprietary information, potential candidates would possess:

• Experience with Glycopeptide Antibiotics: A track record in manufacturing related molecules like vancomycin or daptomycin.
• cGMP Compliance: Facilities that adhere to Current Good Manufacturing Practices (cGMP) as required by regulatory bodies like the FDA and EMA.
• Scale-Up Capabilities: Ability to produce API in commercial quantities.

Companies known for complex API synthesis, particularly in the antibiotics and peptide space, are likely candidates to develop and supply telavancin hydrochloride API. These often include established CDMOs in India and China, as well as specialized manufacturers in Europe and North America.

Hypothetical Supplier Profile:

A capable telavancin hydrochloride API supplier would likely have:

• Core Competencies: Fermentation, semi-synthesis of complex molecules, chiral chemistry.
• Quality Systems: Robust QA/QC departments, documented SOPs, validation protocols.
• Regulatory Experience: DMF (Drug Master File) submission experience with major regulatory agencies (FDA, EMA, PMDA).
• Capacity: Multi-ton annual capacity for complex APIs.

Regulatory and Quality Aspects

The production of telavancin hydrochloride API is subject to stringent regulatory oversight. Manufacturers must comply with cGMP guidelines to ensure the safety, efficacy, and quality of the API. This involves:

• Process Validation: Demonstrating that the manufacturing process consistently produces API meeting predetermined specifications.
• Impurity Profiling: Identifying and controlling process-related impurities and degradants.
• Stability Studies: Assessing the API's stability under various storage conditions.
• Drug Master File (DMF) Submission: Filing a DMF with regulatory authorities (e.g., FDA) provides detailed information about the API manufacturing process, facilities, and quality control. This allows finished drug product manufacturers to reference the DMF in their applications.

The complexity of telavancin’s structure presents significant challenges in controlling impurities, particularly related to stereochemistry and residual starting materials or intermediates. Manufacturers must establish robust analytical methods for their detection and quantification.

Market Dynamics and Future Outlook

The market for telavancin hydrochloride API will be shaped by the eventual expiry of remaining patents, the success of generic drug product manufacturers in obtaining regulatory approval, and the pricing strategies of both originator and generic suppliers.

• Generic Entry: As patent protection wanes, generic manufacturers will aim to produce and market telavancin hydrochloride. This requires significant investment in process development, scale-up, and regulatory filings.
• Pricing Pressure: The entry of generics is expected to drive down the price of telavancin hydrochloride, making it more accessible.
• Therapeutic Alternatives: The market position of telavancin also depends on the availability and efficacy of alternative antibiotics for Gram-positive infections.

The future outlook for telavancin hydrochloride API suppliers hinges on their ability to develop cost-effective and robust manufacturing processes that meet global regulatory standards, and to secure reliable partnerships with generic drug product developers.

Key Takeaways

• Telavancin hydrochloride patents are gradually expiring, creating opportunities for generic API manufacturers.
• Manufacturing telavancin hydrochloride API is complex, requiring specialized expertise in peptide and antibiotic synthesis, fermentation, and advanced purification.
• Key suppliers will likely be CDMOs with demonstrated cGMP compliance and experience in complex API production.
• Regulatory compliance, including cGMP and DMF submission, is critical for API manufacturers.
• The market for telavancin hydrochloride API is expected to grow with the advent of generic competition.

Frequently Asked Questions

What are the primary challenges in telavancin hydrochloride API synthesis?

The primary challenges include the multi-step semi-synthetic process, the requirement for high purity and stereochemical control, and the management of potential impurities arising from complex chemical transformations.

Which regulatory agencies are most critical for API suppliers to engage with?

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are critical. Compliance with their cGMP standards and successful DMF filings are essential for market access in these major regions.

What is the typical lead time for a new API supplier to establish telavancin hydrochloride production?

Establishing production for a complex API like telavancin hydrochloride typically involves 2-4 years for process development, scale-up, validation, and regulatory filings.

How does the chemical complexity of telavancin hydrochloride impact its cost of goods?

The intricate synthesis pathway, specialized raw materials, advanced purification techniques, and rigorous quality control all contribute to a higher cost of goods compared to simpler small-molecule APIs.

Are there any known biosimilar or biobetters for telavancin hydrochloride currently in development?

As telavancin is a semi-synthetic small molecule, the terms biosimilar or biobetter do not directly apply. The market entry for competitive products would be through generic versions of the same API or through novel chemical entities with similar mechanisms of action.

References

[1] VIBATIV® (telavancin) for Injection prescribing information. (2021). Pacira Pharmaceuticals, Inc. [2] Theravance, Inc. (2013). Form 10-K Annual Report. U.S. Securities and Exchange Commission. [3] Pacira Biosciences, Inc. (2018). Form 10-Q Quarterly Report. U.S. Securities and Exchange Commission.